Roumen Deltchev Balabanov

  • 1835 Citations
1994 …2022
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Training Experience

1996Fellowship, Wayne State University
1999Internship, Wayne State University
2002Residency, University of Chicago Hospitals
2004Fellowship, University of Chicago Hospitals

Education/Academic qualification

MD, Medical Academy, Sofia, Bulgaria

… → 1991

Fingerprint Dive into the research topics where Roumen Deltchev Balabanov is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 6 Similar Profiles
Multiple Sclerosis Medicine & Life Sciences
Pericytes Medicine & Life Sciences
Oligodendroglia Medicine & Life Sciences
Relapsing-Remitting Multiple Sclerosis Medicine & Life Sciences
Autoimmune Experimental Encephalomyelitis Medicine & Life Sciences
Neuromyelitis Optica Medicine & Life Sciences
Interferon Regulatory Factor-1 Medicine & Life Sciences
Central Nervous System Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2017 2022

Research Output 1994 2019

16 Citations (Scopus)

Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial

Burt, R. K., Balabanov, R. D., Burman, J., Sharrack, B., Snowden, J. A., Oliveira, M. C., Fagius, J., Rose, J., Nelson, F., Barreira, A. A., Carlson, K., Han, X., Moraes, D., Morgan, A., Quigley, K., Yaung, K., Buckley, R., Alldredge, C., Clendenan, A., Calvario, M. A. & 3 others, Henry, J., Jovanovic, B. & Helenowski, I. B., Jan 15 2019, In : JAMA - Journal of the American Medical Association. 321, 2, p. 165-174 10 p.

Research output: Contribution to journalArticle

Relapsing-Remitting Multiple Sclerosis
Hematopoietic Stem Cell Transplantation
Disease Progression
Randomized Controlled Trials
Group Psychotherapy

Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: A prespecified 2-year interim analysis of STRIVE

Perumal, J., Fox, R. J., Balabanov, R. D., Balcer, L. J., Galetta, S., Makh, S., Santra, S., Hotermans, C. & Lee, L., Jun 8 2019, In : BMC Neurology. 19, 1, 116.

Research output: Contribution to journalArticle

Open Access
Relapsing-Remitting Multiple Sclerosis
JC Virus
Quality of Life
Placebo Effect
Natalizumab

Treatment of natalizumab-associated PML with filgrastim

Stefoski, D., Balabanov, R. D., Waheed, R., Ko, M., Koralnik, I. J. & Sierra Morales, F., May 1 2019, In : Annals of clinical and translational neurology. 6, 5, p. 923-931 9 p.

Research output: Contribution to journalArticle

Open Access
Progressive Multifocal Leukoencephalopathy
Multiple Sclerosis
Immune Reconstitution Inflammatory Syndrome
Therapeutics
Plasma Exchange
4 Citations (Scopus)

B7-H4 modulates regulatory CD4+T cell induction and function via ligation of a semaphorin 3a/Plexin A4/Neuropilin-1 Complex

Podojil, J. R., Chiang, M. Y., Ifergan, I., Copeland, R., Liu, L. N., Maloveste, S., Langermann, S., Liebenson, D., Balabanov, R. D., Chi, H., Chen, L., Vignali, D. A. A. & Miller, S. D., Aug 1 2018, In : Journal of Immunology. 201, 3, p. 897-907 11 p.

Research output: Contribution to journalArticle

Semaphorin-3A
Neuropilin-1
Regulatory T-Lymphocytes
Ligation
Semaphorins
87 Citations (Scopus)

Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis

Burt, R. K., Balabanov, R., Han, X., Sharrack, B., Morgan, A., Quigley, K., Yaung, K., Helenowski, I. B., Jovanovic, B., Spahovic, D., Arnautovic, I., Lee, D. C., Benefield, B. C., Futterer, S., Oliveira, M. C. & Burman, J., Jan 20 2015, In : JAMA - Journal of the American Medical Association. 313, 3, p. 275-284 10 p.

Research output: Contribution to journalArticle

Relapsing-Remitting Multiple Sclerosis
Hematopoietic Stem Cell Transplantation
Multiple Sclerosis
Cyclophosphamide
Nervous System